Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
SEATTLE and SOUTH SAN FRANCISCO, March 03, 2016 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report fourth quarter and year end 2015 financial results after the close of U.S. financial markets on Thursday, March 10, 2016. Immune Design management will host a webcast and conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on March 10, 2016 to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 844-831-3023 for domestic callers and 920-663-6275 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at http://ir.immunedesign.com/events.cfm and will be archived there for 90 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 61885687.
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.
Media Contact Julie Rathbun Rathbun Communications [email protected] 206-769-9219 Investor Contact Shari Annes Annes Associates [email protected] 650-888-0902
